FDA
Ideas that could help FDA
- Neuro-Plasticity Biomarker Tracker
A diagnostic imaging tool that measures the persistent reduction in connectivity between the anterior hippocampus and the default mode network to quantify the therapeutic 'window' of psychedelic treatment.
Why it helps: The agency requires objective, measurable endpoints (biomarkers) to approve new psychedelic-based pharmaceutical treatments.
- Psychedelic Response Biomarker Assay
A diagnostic imaging protocol to predict a patient's subjective response to psilocybin based on their specific brain desynchronization patterns.
Why it helps: The agency requires objective, quantifiable endpoints to approve new psychedelic-based pharmaceutical treatments.
- LLM Safety & Alignment Auditor
A compliance tool that uses standardized benchmarks to certify that a fine-tuned LLM meets specific safety and alignment requirements before deployment.
Why it helps: Could use such a framework to set standards for LLMs used in medical diagnostic support or drug discovery documentation.
- Non-Hallucinogenic TrkB Allosteric Modulator
A pharmaceutical compound designed as a positive allosteric modulator (PAM) of the TrkB receptor to induce neuroplasticity and antidepressant effects. By avoiding 5-HT2A receptor activation, it aims to provide the therapeutic benefits of psychedelics without the associated hallucinogenic effects.
Why it helps: A non-hallucinogenic version of these compounds would have a significantly simpler regulatory and safety profile for approval than scheduled psychedelics.
- Bio-Optimized 3D-Printed Aligner Resin
A high-performance 3D-printing resin for direct-printed aligners designed to minimize water-induced mechanical degradation and chemical leaching. The formulation focuses on high-conversion monomers to ensure structural stability and biocompatibility in the oral environment.
Why it helps: A material with lower leachable compounds simplifies the biocompatibility certification process for new dental devices.